Search results
Results From The WOW.Com Content Network
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [7] [8]
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019. [1] Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine.
Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies. [6] [7] [8] In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do ...
The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths. The Instituto Butantan imported the first 6 million doses of CoronaVac in a collaboration with the Chinese company Sinovac Biotech.
e. The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3] [4] [5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm 's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting in the ...
For the Netherlands, based on overall excess mortality, an estimated 20,000 people died from COVID-19 in 2020, [9] while only the death of 11,525 identified COVID-19 cases was registered. [8] The official count of COVID-19 deaths as of December 2021 is slightly more than 5.4 million, according to World Health Organization's report in May 2022.
v. t. e. CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines. [6]
Share of people who received at least one dose of COVID-19 vaccine in the world. COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. [1] As of October 2023, 51.8% of the continent's population is fully vaccinated with ...